ストックスクリーナーアプリを入手
5.71
2.88%
0.16
アフターアワーズ：
5.73
0.02
+0.35%
前日終値:
$5.55
開ける：
$5.57
24時間の取引高:
691.50K
Relative Volume:
0.74
時価総額：
$406.26M
収益：
$14.20M
当期純損益:
$-49.59M
株価収益率:
-6.7783
EPS:
-0.8424
ネットキャッシュフロー:
$-35.25M
1週間 パフォーマンス:
+10.87%
1か月 パフォーマンス:
+13.52%
6か月 パフォーマンス:
+185.50%
1年 パフォーマンス:
+611.97%
1日の値動き範囲:
$5.40
$5.75
1週間の範囲:
$5.0744
$5.75
52週間の値動き範囲:
$0.7101
$5.75
Opus Genetics Inc Stock (IRD) Company Profile
Compare IRD vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IRD
Opus Genetics Inc
|
5.71 | 394.88M | 14.20M | -49.59M | -35.25M | -0.8424 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Opus Genetics Inc Stock (IRD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-30 | 開始されました | Cantor Fitzgerald | Overweight |
| 2026-03-16 | 開始されました | Oppenheimer | Outperform |
| 2026-01-20 | 開始されました | BTIG Research | Buy |
| 2025-12-10 | 開始されました | B. Riley Securities | Buy |
| 2025-11-25 | 開始されました | Piper Sandler | Overweight |
| 2025-10-29 | 開始されました | Wedbush | Outperform |
| 2025-10-16 | 開始されました | Chardan Capital Markets | Buy |
| 2025-04-11 | 開始されました | Craig Hallum | Buy |
| 2024-11-13 | 再開されました | H.C. Wainwright | Buy |
すべてを表示
Opus Genetics Inc (IRD) 最新ニュース
Opus Genetics (IRD) price target increased by 23.44% to 9.73 - MSN
Opus Genetics secures up to $155M financing from Oberland Capital - MSN
Craig-Hallum Maintains Opus Genetics(IRD.US) With Buy Rating - Moomoo
Opus Genetics Receives $10.11 Consensus Target Price - National Today
Ideas Watch: What is the earnings history of Opus Genetics IncPortfolio Return Report & Reliable Entry Point Alerts - baoquankhu1.vn
Night Vision Disturbances Pipeline 2026: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | Opus Genetics, Viatris, Nevakar, Vyluma, Pfizer, Allergan, AbbVie - Barchart.com
Night Vision Disturbances Pipeline 2026: MOA, ROA, - openPR.com
Opus Genetics to Present Key Ophthalmology Research at ASCRS Annual Meeting 2026 - Quiver Quantitative
Opus Genetics Announces Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting - Bitget
Profit Review: Is Opus Genetics Inc in a consolidation phase2026 Technicals & Community Verified Trade Signals - baoquankhu1.vn
Opus Genetics Receives 'Moderate Buy' Rating from Analysts - National Today
Opus Genetics Enters Strategic Financing Agreement With Oberland Capital - VisionMonday.com
Forecast Cut: Will Opus Genetics Inc be affected by tariffsWeekly Investment Summary & Growth Focused Entry Point Reports - baoquankhu1.vn
Opus Genetics, Inc. (R3X1.F) stock price, news, quote and history - Yahoo Finance UK
Opus Genetics enters change in control bonus agreements with key executives - Investing.com India
Opus Genetics enters change in control bonus agreements with key executives By Investing.com - Investing.com Australia
BTIG Maintains Opus Genetics(IRD.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Opus Genetics Adopts Change-in-Control Executive Bonus Agreements - TipRanks
Opus Genetics Secures Up to $155 Million in Non-Dilutive Funding from Oberland Capital to Advance Gene Therapy Pipeline for Inherited Retinal Diseases - Minichart
Opus Genetics (NASDAQ: IRD) adds change-in-control tax reimbursements - Stock Titan
Opus Genetics Secures Major Non-Dilutive Funding Facility - TipRanks
Opus Genetics Secures Up to $155 Million Notes and Raises $5 Million in Equity Financing - TradingView — Track All Markets
Opus Genetics Solidifies Leadership Position in Gene Therapy Development for Inherited Retinal Diseases with Strategic Long-Term Financing by Oberland Capital - Bitget
Pullback Watch: How does Opus Genetics Inc correlate with Nasdaq2026 Trends & AI Driven Stock Reports - baoquankhu1.vn
Chardan Capital Initiates Coverage of Opus Genetics (IRD) with Buy Recommendation - MSN
Opus Genetics (IRD) lands $155M Oberland deal to fund gene therapy pipeline - Stock Titan
Opus Genetics, Inc. (IRD) stock price, news, quote and history - Yahoo Finance UK
Opus Genetics secures up to $155M financing from Oberland Capital By Investing.com - Investing.com South Africa
Oberland Capital has officially committed to a $5 million equity investment in Opus Genetics Inc at a price of $4.48 per share. - bitget.com
Opus Genetics Secures Up to $155 Million Financing From Oberland Capital - marketscreener.com
Opus Genetics Inc announced strategic financing agreement with Oberland Capital Management LLC - marketscreener.com
Opus Genetics Inc Announced Strategic Financing Agreement With Oberland Capital Management Llc - TradingView — Track All Markets
Opus Genetics Secures $155 Million Strategic Financing Agreement with Oberland Capital to Advance Gene Therapy Programs - Quiver Quantitative
Opus Genetics Solidifies Leadership Position in Gene Therapy Development for Inherited Retinal ... - Bluefield Daily Telegraph
IRD Technical Analysis & Stock Price Forecast - intellectia.ai
Opus Genetics Shows Proper Planning Is Key To Adaptive Trial Design - Clinical Leader
Aug Volume: Can Opus Genetics Inc navigate macro headwinds2026 Spike Watch & Free Fast Gain Swing Trade Alerts - baoquankhu1.vn
Bull Run: Can Opus Genetics Inc reach all time highs this year2026 Analyst Calls & Reliable Entry Point Trade Alerts - baoquankhu1.vn
Opus Genetics (IRD) Receives Overweight Rating from Cantor Fitzg - GuruFocus
Cantor Fitzgerald Initiates Coverage on Opus Genetics - National Today
Opus Genetics (NASDAQ:IRD) Now Covered by Analysts at Cantor Fitzgerald - MarketBeat
This Live Nation Entertainment Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Cantor Fitzgerald Initiates Opus Genetics(IRD.US) With Buy Rating, Announces Target Price $15 - Moomoo
Short Interest in Opus Genetics, Inc. (NASDAQ:IRD) Grows By 81.3% - MarketBeat
Risk Analysis: Is Opus Genetics Inc stock a good pick for beginners2026 Macro Impact & Verified Entry Point Detection - baoquankhu1.vn
Opus Genetics Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2026 - Sahm
Loss Report: Will Opus Genetics Inc benefit from current market trends2026 Bull vs Bear & Free Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
Opus Genetics Inc (IRD) 財務データ
収益
当期純利益
現金流量
EPS
2.69%
0.25%
大文字化:
|
ボリューム (24 時間):